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ABSTRACT. Early prediction of human clearance is often challenging, in particular for
the growing number of low-clearance compounds. Long-term in vitro models have been
developed which enable sophisticated hepatic drug disposition studies and improved
clearance predictions. Here, the cell line HepG2, iPSC-derived hepatocytes (iCell®), the
hepatic stem cell line HepaRG™, and human hepatocyte co-cultures (HμREL™ and
HepatoPac®) were compared to primary hepatocyte suspension cultures with respect to their
key metabolic activities. Similar metabolic activities were found for the long-term models
HepaRG™, HμREL™, and HepatoPac® and the short-term suspension cultures when
averaged across all 11 enzyme markers, although differences were seen in the activities of
CYP2D6 and non-CYP enzymes. For iCell® and HepG2, the metabolic activity was more
than tenfold lower. The micropatterned HepatoPac® model was further evaluated with
respect to clearance prediction. To assess the in vitro parameters, pharmacokinetic modeling
was applied. The determination of intrinsic clearance by nonlinear mixed-effects modeling in
a long-term model signiﬁcantly increased the conﬁdence in the parameter estimation and
extended the sensitive range towards 3% of liver blood ﬂow, i.e., >10-fold lower as compared
to suspension cultures. For in vitro to in vivo extrapolation, the well-stirred model was used.
The micropatterned model gave rise to clearance prediction in man within a twofold error for
the majority of low-clearance compounds. Further research is needed to understand whether
transporter activity and drug metabolism by non-CYP enzymes, such as UGTs, SULTs, AO,
and FMO, is comparable to the in vivo situation in these long-term culture models.
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INTRODUCTION
In drug discovery programs, the predictions of human
pharmacokinetics and recommendation of dose and dosing
regimen are essential tasks to achieve safe and efﬁcacious
treatments. For physiologically based modeling and simulation
efforts, human clearance prediction from in vitro data is an
important component. Determinations of in vitro intrinsic
clearances are routinely conducted in pharmaceutical research
via in vitro liver models, such as microsomes or hepatocytes (1,2).
However, the activity of drug metabolizing enzymes in these
widely used in vitro models declines within hours (3), and
therefore, depletion of compounds with low turnover (<10%)
cannot be determined with conﬁdence. As the number of low-
clearance compounds in pharmaceutical programs increases due
to the application of highly effective metabolic clearance
reduction strategies in lead optimization to allow once-daily
administration of moderate drug quantities (4), more sophisti-
cated in vitro liver models are required (5). For example, models
where themetabolic activity is prolonged for up to 2–4 weeks can
extend the sensitive range for clearance determination. Long-
term in vitro liver models, such as the hepatic stem cell line
HepaRG™ (6), micropatterned HepatoPac® co-cultures of
human hepatocytes with mouse embryonic 3T3 ﬁbroblasts cells
(7), and HμREL™ hepatocyte/ﬁbroblast co-culture plates (8), as
well as alternative approaches for low clearance determination,
such as the relaymethod with suspension hepatocyte cultures (9),
are being intensively explored. Chan et al. (10) studied the
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prediction of in vivo clearances of reference compounds in
HepatoPac® co-cultures, which are engineered to have extended
cell viability and metabolic activity. Here, they reported the
superiority of the HepatoPac® system compared to suspension
cultures for predicting low in vivo clearances. Recently, Bonn
et al. (11) reported the successful application of plated hepato-
cytes, HepaRG™ and HμREL™ co-cultures, for low intrinsic
clearance determination and found slightly better performance of
the HμREL™ system. In this study, we report the metabolic
activity across a diverse set of phase I and phase II enzyme
markers in different in vitro liver models as this is an important
prerequisite for successful clearance determination across struc-
tural classes. Additionally, for the ﬁrst time, we applied
pharmacokinetic (PK) modeling using a nonlinear mixed-effects
approach for low in vitro clearance estimations with a long-term
liver model for reference and in-house Roche compounds. The
nonlinear mixed-effects approach is routinely applied for model-
ing clinical PK data to quantify population mean kinetics, inter-
individual variability, and residual variability, including intra-
individual variability and measurement error (12). The nonlinear
mixed-effects approach is preferred as it estimates residual
variability in contrast to the naive pooled data approach, where
all data are ﬁtted together, or the two-stage approach, where
individual data are ﬁtted separately and then the individual
parameter estimates are combined (13). By applying the
nonlinear mixed-effects approach to in vitro data, where the
statistical unit is the well, the conﬁdence in the clearance estimate
is increased as the pharmacokinetic parameters and residual
variability can be derived. Furthermore, we compare clearance
predictions in man for reference compounds in the long-term
in vitro liver model, HepatoPac®, and in suspension cultures
using the same hepatocyte donor. Finally, we describe for the ﬁrst
time human clearance predictions for clinical development
candidates with different physicochemical properties and clear-
ance pathways than reference compounds, applying the well-




Midazolam, 1′-hydroxymidazolam, and Roche compounds
RO1–RO9 were synthesized at F.Hoffmann-La Roche Ltd.
(Basel, Switzerland). Dextromethorphan (D-2531), diclofenac
(D-6899), tolbutamide (T0891), bupropion (B-102), daunorubi-
cin (30450), benzydamine (B5524),O6-benzyl guanine (B2292),
sulfamethazine (S6256), quinidine (Q-3625), warfarin (A2250),
dextrophan (D127), 4-hydroxydiclofenac (H3661), 8-oxo-O6-
benzylguanine (B2292), 7-hydroxycoumarin glucuronide
(UC263), 7-hydroxycoumarin sulfate (UC283), chlorpromazine
hydrochloride (C8138), Trypan blue (T8154), William’s E
medium (W-1878), hydrocortisone (H-0888), insulin (I-1882),
penicillin/streptomycin (P-0781), bovine serum albumin stan-
dard 2 mg/mL (BCA ampules from Pierce, no. 2320), BCA
Protein Assay Reagent A (Pierce, no. 23223), and Reagent B
(Pierce, no. 23224), human serum albumin (A3782), α1-acid
glycoprotein (G9885), and ﬂat-bottomNunc 96-well plates were
purchased from Sigma-Aldrich (St. Louis, MO, USA). SN-38
(S589950), SN-38 glucuronide (S589980), hydroxybupropion
(H830675), benzydamine N-oxide (B209960), hydroxytacrine
(A629900), daunorubicinol (D194510), andN-acetyl-sulfameth-
azine (A187850) were purchased from Toronto Research
Chemicals (Toronto, Canada). Tacrine (no. 70240, Cayman,
Ann Arbor, Michigan, USA), 7-hydroxycoumarin (Acros no.
12111, Thermo Fisher Scientiﬁc, New Jersey, USA), nifedipine
(Alfa Aesar no. J62811, Thermo Fisher Scientiﬁc), and
gentamycin (no. 4-07F00-H, Amimed, London, UK) were
purchased from different sources. Penicillin/streptomycin (no.
15140-122), GlutaMax-I (no. 31966), L-glutamine (no. 25030-
024), fetal calf serum (no. 16000), and collagen I-coated 96-well
plates (no. A11428-03) were purchased from Gibco/Life Tech-
nologies (Grand Island, NY, USA). Matrigel matrix phenol red-
free (no. 356237) was obtained from BD Bioscience (Franklin
Lakes, NJ, USA). For urea quantiﬁcation, the urea nitrogen test
(0580-250) from StanBio Laboratory (Boerne, TX, USA) was
used. For human albumin quantiﬁcation, the two-site enzyme-
linked immunoassay (ELISA) from GenWay Biotech, Inc (San
Diego, CA, USA) was employed. For human, commercially
available primary pooled cryopreserved hepatocytes from non-
transplantable liver tissues were purchased (no. X008001, Lots
ECO (ten donors) and URK (ﬁve donors); no. X008052, Lot
JJR (ten donors)) from BioreclamationIVT (NY, USA).
HepaRG™ cells (no. HPR101) and growthmedium supplement
(no. ADD710) were received from Biopredics International
(Rennes, France). HepG2 cells (lot no. 121205) were purchased
from Mitosciences (Oregon, USA). Cryopreserved induced
pluripotent stem cell (iPSC)-derived hepatocyte-like cells
(iCell® hepatocytes) were purchased from Cellular Dynamics
International (Wisconsin, USA). Human HepatoPac® cultures
were acquired from Ascendance Corporation (Medford, MA)
and prepared from a lot (unpooled) of cryoplateable hepato-
cytes (Lot 3121A, BioreclamationIVT, Lot TLQ). Human
HμREL™ cultures were acquired fromHμREL™Corporation
(North Brunswick, NJ) and prepared from pooled (ﬁve donors)
cryoplateable hepatocytes (Lot HU1007, BioreclamationIVT,
Lot YMD). The pooled and frozen plasma from human (Lot
PLA022C0AK113) was obtained from BioreclamationIVT.
Zeiss Axio Vision SE64 Rel. 4.9.1 microscope (Carl Zeiss AG
Corporate, Oberkochen, Germany) was used for cell images.
Teﬂon equilibrium dialysis plate (96-well, 150 μL, half-cell
capacity) and cellulose membranes (12- to 14-kDa molecular
weight cutoff) were purchased from HT-Dialysis (Gales Ferry,
CT, USA). Human fresh blood was obtained internally (F.Hoff-
mann-La Roche Ltd.). DMSO stock solutions for the com-
pounds were used with ﬁnal DMSO concentrations of 0.1% in
the incubation samples.
Suspension Cultures
Primary pooled cryopreserved hepatocytes from different
lots were reconstituted in warm William’s E media containing
10% fetal calf serum, 0.048 mg/mL hydrocortisone, 0.004 mg/
mL insulin, 0.05 mg/mL streptomycin, 50 U/mL penicillin,
0.01 mg/mL gentamycin, and 0.4 mM L-glutamine. Viability of
hepatocytes after reconstitution was at least 80%. Suspension
cultures of 1million (Mio) cells per milliliter were then prepared
using the thawingmedium.After the addition of test compounds
at different concentrations to the wells (100 μL), the 96-well
hepatocyte suspension cultures plates were shaken (900 rpm) in
a 5% CO2 atmosphere at 37°C and sampling was done at
different time points up to 2 h.
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HepaRG™
HepaRG™ cells were cultured at 37°C in a humidiﬁed
atmosphere with 5% CO2 in complete HepaRG™ growth
medium consisting of William’s E medium, growth medium
supplement, and 1% (v/v) GlutaMAX-I. To initiate differen-
tiation, 0.9% (v/v) DMSO was added to the growth medium
on conﬂuent cells. After 1 week, the medium was replaced by
complete differentiation medium (HepaRG™ growth me-
dium supplemented with 1.8% (v/v) DMSO), in which cells
were maintained for approximately 4 weeks with differenti-
ation medium renewal every 7 days. Differentiated
HepaRG™ cells displayed hepatocyte-like cell islands
surrounded by a monolayer of biliary-like cells. For metabolic
experiments, differentiated HepaRG™ cells were seeded into
collagen I-coated 96-well plates at 60,000 cells per well.
HepatoPac®
HepatoPac® cultures were received from Ascendance and
recovered for 2 days after shipment by changing the medium
and keeping them at 10% CO2 atmosphere and 37°C. The
hepatic functionality of the HepatoPac® cultures was assessed
in detail byKhetani et al. (14). For the used donor lot 3121A, the
albumin and urea production was provided in the Ascendance
speciﬁcation sheet, e.g., 32 μg/day per Mio cells for albumin and
290 μg/day per Mio cells for urea at day 8 of culture. Similar
results for albumin and urea production were found after
receiving the HepatoPac® cultures after shipment using an
ELISA test for albumin quantiﬁcation and a standard urea
nitrogen kit for urea quantiﬁcation. The metabolic functionality
was evaluated by studying the clearance of midazolam at
different days of the long-term cultures, conﬁrming data from
the provider that themetabolic activity is conserved up to day 15
in culture. Prior to the addition of test substances, the cultures
were washed with 64 μL serum-free Dulbecco’s modiﬁed
Eagle’s medium specially formulated for HepatoPac® cultures
(Ascendance Corporation). Incubations containing only mouse
ﬁbroblast cells served as the controls.
HμREL™
Co-culture plates were shipped in maintenance medium
at 37°C from HμREL™. After arrival, the cultures were
recovered in HμREL™ PlatinumHeps maintenance medium
overnight at 5% CO2 atmosphere and 37°C. Prior to the
addition of test substances, the cultures were washed with
100 μL HμREL™ PlatinumHeps media specially formulated
for HμREL™ cultures.
iPSC-Derived Hepatocyte-Like Cells
Cryopreserved iPSC-derived hepatocyte-like cells
(iCell®) were thawed according to the manufacturer’s
instruction, resuspended in medium D (provided by the
manufacturer) containing 0.25 mg/mL Matrigel, and seeded
on collagen-coated 96-well plates at 140,000 cells per well.
Cells were cultured at 37°C in a humidiﬁed atmosphere with
5% CO2. The culture medium was replaced 24 h post-plating
and every 2 days before conducting metabolic activity studies.
HepG2
HepG2 cells were cultured at 37°C in a humidiﬁed
atmosphere with 5% CO2 in complete HepG2 medium
consisting of Dulbecco’s modiﬁed Eagle’s medium,
GlutaMAX-I containing penicillin/streptomycin, and 10%
heat-inactivated fetal calf serum. For experiments, HepG2
cells were trypsinized and seeded into collagen I-coated 96-
well plates at 25,000 cells per well.
Metabolic Activity of In Vitro Liver Models
For metabolic activity determination, the following
enzyme substrates were added to the in vitro liver models in
a 96-well format and incubated at 5% CO2 atmosphere and at
37°C. Midazolam, dextromethorphan, diclofenac, bupropion,
benzydamine, daunorubicin, 7-hydroxycoumarin, O6-benzyl
guanine, and tacrine were incubated at 1 μM and sulfameth-
azine and SN-38 at 20 and 50 μM, respectively. At deﬁned
time points, samples were drawn and quenched with aceto-
nitrile (volume ratio, 1:2) containing 0.1 mM chlorpromazine
as internal standard. Samples were then cooled, centrifuged,
and quantiﬁed by using liquid chromatography and mass
spectrometry (LC-MS/MS). The parameter settings for LC/
MS analyte detection in positive or negative ion multiple
reaction monitoring (MRM) mode are summarized in Sup-
plemental 1. The Shimadzu HPLC (high-pressure liquid
chromatography) system consisted of 10ADVP pumps con-
nected to a 5000 AB Sciex mass spectrometer equipped with
a TurboIonSpray source (IonSpray Voltage 5500 V in positive
mode and −4500 V in negative mode) and a HTS CTC PAL
autosampler. For 1′-hydroxymidazolam, benzydamine N-
oxide, daunorubicinol, N-acetyl-sulfamethazine, SN-38 glucu-
ronide, 8-oxo-O6-benzylguanine, hydroxybupropion, 4-
hydroxydiclofenac, dextrorphan, and hydroxytacrine, a 50 ×
2-mm Phenomenex Gemini C18 110A resin analytical column
with 5 μm particle size was used. 7-Hydroxycoumarin
glucuronide and sulfate were chromatographed using a 50-
cm × 2-mm Phenomenex Synergi Hydro-RP 80 Å resin
analytical column with 4 μm particle size at 40°C. Mobile
phase A was 0.2% formic acid in water and mobile phase B
was 0.1% formic acid in 95:5 water/methanol. Aliquots (1 μl)
of the centrifuged sample solutions were injected and
transferred onto the analytical column at a ﬂow rate of
0.50 mL/min using 95% mobile phase A. To elute the
compounds, a high-pressure linear gradient from 5 to 95%
B in 98 s was applied. The precision and accuracy of the
standard and quality control (QC) samples were between 80
and 120%. Data analysis was performed using weighted (1/x2)
linear regression on analyte/internal standard area ratios. For
data analysis, Analyst software (version 1.6.2, SCIEX,
Framingham, USA) was used. To derive metabolic rates, the
determined concentrations of the metabolites were plotted
against time and a linear ﬁt made to the data with emphasis
upon the initial linear rate. The linear rate was then used to
derive at the metabolite formation rate (in picomoles per
minute per Mio cells) after normalization by the protein
content of the cells. For the long-term liver co-culture model
HepatoPac®, metabolic rates were also determined in mouse
embryonic 3T3 ﬁbroblast control plates only.
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In Vitro Clearance Assessment
For in vitro clearance assessment, incubations of the test
compounds at different concentrations were performed in the 96-
well format in vitro liver models (5% CO2 atmosphere and at
37°C). At deﬁned time points, either an aliquot of the cell
incubation medium was taken or the whole well (for suspension
cultures) was quenched with acetonitrile (volume ratio, 1:2)
containing 0.1 mM chlorpromazine as internal standard. The
samples were then cooled and centrifuged before analysis by LC-
MS/MS. LC-MS/MS was used for the quantiﬁcation of the
reference and Roche compounds. The HPLC system consisted of
Shimadzu pumps. An API6500, QTRAP 5500, or a QTRAP4000
AB Sciex mass spectrometer equipped with a TurboIonSpray
source (IonSpray Voltage 5500 V in positive mode and −4500 V in
negativemode) and aHTSCTCPALautosamplerwere used. The
analytical columnwas a 20-cm× 2.1-mm Supelco Ascentis Express
C18 with 2.7 μm particle size at different temperatures for the
analytes. For RO1, mobile phase A was 10 mM ammonium
formate adjusted to pH 3.7with formic acid in 95:5 water/methanol
and mobile phase B was 100% acetonitrile. For RO2, RO4, RO6,
RO7, RO9, midazolam, dextromethorphan, tolbutamide, and
warfarin, mobile phase A was 0.5% formic acid in 95:5 water/
methanol and mobile phase B was methanol. For RO3, mobile
phase Awas 0.5% formic acid in water and mobile phase B was
0.5% formic acid in acetonitrile. For quinidine, diclofenac, and
nifedipine, mobile phase Awas 20 mM of ammonium bicarbonate
in 95:5 water/methanol and mobile phase B was 100% methanol.
Aliquots (1 or 5 μL) of the centrifuged sample solutions were
injected and transferred at the analytical column at ﬂow rates
between 500 and 600 μL/min. To elute the compounds, high-
pressure linear gradients were applied. Detections were achieved
in positive or negative ionMRMmodewith the parameter settings
given in Supplemental 1. Data analysis was performed using
quadratic regression with 1/x2 weighting on peak area ratios. The
precision and accuracy of the standard and QC samples were
between 80 and 120%. Analyst software (version 1.6.2, SCIEX)
was used for data processing. For determination of the intrinsic
clearance, either individual curve ﬁtting (medium to high
clearance) or pharmacokinetic modeling (low clearance) using a
nonlinear mixed-effects approach was applied.
Determination of Intrinsic Clearance Values by Individual
Curve Fitting for Medium- to High-Clearance Compounds
A linear ﬁt was applied to the ln(concentration)–time
proﬁles for each dose level using XLﬁt software (version 5.3.1.3,
ID Business Solutions Limited, Guildford, UK). The slope of the









Determination of Intrinsic Clearance Values for Low-
Clearance Compounds in Long-Term Liver Models by
Pharmacokinetic Modeling Using a Nonlinear Mixed-Effects
Approach
The objective of this modeling was to improve the accuracy
and precision of the intrinsic clearance determination by
performing a simultaneous compartmental model ﬁt to the
in vitro time–concentration proﬁles from multiple dose levels.
Data were analyzed by using a nonlinear mixed-effects PK
modeling approach in the Monolix® software (version 4.22,
Lixoft–Incuballiance, Orsay, France) (15). The statistical unit
was the well. Two types of PK models were tested: one with











Km⋅αþ C0 tð Þ
⋅C
0
tð Þ; C0 0ð Þ ¼ C0 ð3Þ
where C′ is the uncorrected concentration, ke is the elimina-
tion rate, Km the Michaelis–Menten constant, α a correction
factor (volume), Vm the maximal velocity, and C0 the
theoretical initial concentration.
In both cases, the simulated concentration is described






where α is a correction between the theoretical initial
concentration and the model projected initial concentration.

















The selection of an appropriate PK and error model was
performed considering statistical criteria (improvement of the
objective function and Akaike criterion), precision of parameter
estimates, and diagnostic plots (observed versus predicted, predic-
tion distribution, visual predictive check, and distribution of
residuals).
For the long-term liver co-culture model HepatoPac®,
elimination rates were also determined in ﬁbroblast control
plates only. The ﬁbroblasts were treated in the same manner as
the HepatoPac® plates. Because each well in the HepatoPac
plates has 75% surface area as ﬁbroblasts and 25% surface area
as hepatocytes (14), the determined elimination rates from the
ﬁbroblast cultures were multiplied by 0.75 and then subtracted
from the values determined in the HepatoPac plates to correct
for compound adsorption phenomena and non-hepatic clear-
ance by ﬁbroblasts in the co-cultures.
The intrinsic clearance value was then calculated with
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Protein Content of the Different In Vitro Liver Models
For the protein content determination, cultures were washed
twice with PBS and centrifuged in the case of suspension cultures.
The supernatant was discarded and 1%Triton-X-100 (SURFACT-
AMPS X-100) in water was added to the cells. After mixing, the
cell lysates were kept for 1 h at 4°C and vortexed from time to time
before they were stored overnight at −20°C. The samples were
then thawed and centrifuged; the supernatant was used for the
protein content determination. The protein content was measured
by the Pierce BCA assay kit following the standard protocol. For 1
Mio cells of hepatocyte suspension cultures, the protein content
was 1 mg/mL. Protein contents of 0.6 and 1.5 mg/mL were found
for theHepaRG™ andHepG2 96-well plate cultures, respectively.
The iPSC-derived hepatocyte-like cells (iCell®) had a protein
content of 1.4mg/mL. ThemicropatternedHepatoPac® co-culture
plates contained 3200 (in a 96-well plate) hepatocytes per well, as
speciﬁed in the HepatoPac® donor speciﬁcation (3121A) sheet
provided by the supplier. A protein content of 0.05 mg/mL
(0.032 mg per well) was therefore applied for the 96-well
HepatoPac® format. For the HμREL™ long-term hepatocyte
co-cultures in 96-well plates, a protein content of 0.3 mg/mL was
used as speciﬁed by the supplier.
Plasma Protein Binding Determination and Binding to
Plasma Proteins
The determination of unbound compound was per-
formed in human plasma and in plasma protein buffer
solution (45 g/L human serum albumin and 0.7 g/L α1 acid
glycoprotein in phosphate buffer, pH 7.4, respectively) using
a 96-well format equilibrium dialysis device with a molecular
weight cutoff membrane of 12–14 kDa, as described else-
where (16,17). The derived samples from each dialysis were
then quenched with acetonitrile (ratio, 1:2) containing an
internal standard, centrifuged, and quantiﬁed by LC-MS/MS.
Blood-To-Plasma Ratios
Freshly drawn blood was centrifuged at low speed
(600×g) for 3 min to generate a small erythrocyte-free plasma
layer. DMSO stock solutions of compounds were then spiked
into the erythrocyte-free plasma layer and immediately mixed
and put on a KS130C Mixer™ (IKA® Werke GmbH & Co.,
Staufen, Germany) at 37°C. After 30 min, a whole blood
sample was drawn and the rest of the blood sample was
centrifuged (3000×g for 3 min). The derived blood and
plasma samples were then quenched with an acetonitrile/
water mixture containing an internal standard, centrifuged,
and quantiﬁed by LC-MS/MS.
LogD and pKa Determination
The logD values were determined as published previously
(18). The pKa determinations were done by mean of the Sirius
Technology according to the Sirius technical applications notes (19).
In Vitro to In Vivo Extrapolation of In Vitro Clearance
Assessments
Scaling of In Vitro Intrinsic Clearance to Whole Liver and
In Vivo Total Blood Clearance
The in vitro intrinsic clearance value Clint (in microliters per
minute per milligram protein) was scaled to the in vivo
equivalent whole liver intrinsic clearance Liver Clint (in liters
per hour) using an average liver weight and the
hepatocellularity (Eq. 8), whereas 1 mg protein corresponds to
1 Mio cells. The in vitro whole liver intrinsic unbound clearance
In vitro Clint (in milliliters per minute per kilogram) normalized
by body weight is given in Eq. 9. The predicted in vivo total
blood clearance Clblood (in liters per hour) was then derived by
applying the well-stirred model, as given in Eq. 10. The
physiological data used to scale in vitro intrinsic clearances were
23mLmin−1 kg−1 for liver blood ﬂow, 70 kg for bodyweight, and
1.8 kg for liver weight for human. In addition, a scaling factor of
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Different Protein Binding Assumptions
Conventional (20,21) and direct scaling (22,23)
approaches and the scaling approach by Poulin et al. (24,25)
were explored. For the conventional approach, the fuinc
values of the studied compounds were experimentally deter-
mined. Direct scaling assumes that the fraction unbound in
plasma is equal to the fraction unbound in the in vitro system.
The scaling approach by Poulin et al. (24,25) introduces the
fraction unbound in liver, which is then used instead of the
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fraction in plasma. The derivation of the fraction unbound in
liver is described elsewhere (24).
Determination of Apparent In Vivo Intrinsic Clearance
Apparent in vivo unbound intrinsic clearance In vivo Clint
(in liters per hour) was calculated from the observed in vivo
plasma clearance Clplasma (in liters per hour), fraction unbound
in plasma, and average hepatic blood ﬂow using the well-stirred
model (Eq. 11). The apparent in vivo intrinsic clearance In vivo
Clint (in milliliters per minute per kilogram) normalized by body
weight is given in Eq. 12. Blood clearance Clblood (in liters per
hour) and unbound fraction in blood (fub) were determined




































Accuracy and Precision of Predictions
The accuracy of Clint predictions for a set of compounds
was assessed using the maximal fold error, average fold error
(afe), and absolute average fold error metric using Eqs. 13,
14, and 15. The precision of the prediction for a data set was
assessed using the root mean squared error (rmse) applying
Eq. 16. The size of the data set is represented in Eqs. 14 and
15 as n. In addition, the concordance correlation coefﬁcient
global (CCC) was calculated as described by Lin (26).
maximal fold error af eð Þ ¼ 10max log predictedobservedj j½  ð13Þ





















Metabolic Activity of In Vitro Liver Models
Table I summarizes the metabolite formation rates of a
diverse set of enzyme markers in HepG2, iPSC-derived hepato-
cyte-like cells (iCells®), HepaRG™, HepatoPac® (single do-
nor), HμREL™ (pooled, ﬁve donors), and primary pooled
cryopreserved hepatocytes in suspension cultures (several lots,
ﬁve to ten donors). The used primary hepatocyte lots were similar
in their cytochrome P450 activities, as speciﬁed by the suppliers.
The marker reactions were midazolam 1′-hydroxylase (cyto-
chrome P450 3A4, CYP3A4), dextromethorphanO-demethylase
(CYP2D6), diclofenac 4′-hydroxylase (CYP2C9), bupropion
hydroxylase (CYP2B6), tacrine hydroxylase (CYP1A2),
benzydamine N-oxidation (ﬂavin monooxygenase, FMO), dau-
norubicin reductase (aldo-keto reductase, AKR), O6-
benzylguanine-8-oxidase (aldehyde oxidase, AO), sulfametha-
zine N-acetylase (N-acetyltransferase 2, NAT2), SN-38
glucuronation (UDP glucuronosyltransferase 1A1, UGT1A1),
7-hydroxycoumarin glucuronidation (UDP glucuronosyltransfer-
ase,UGT), and sulfation (sulfotransferases, SULT). The different
cell morphologies of the studied in vitro liver models are given in
Fig. 1. HepG2 and HepaRG™ cells showed the expected
epithelial-like morphology and the typical irregular cell shape,
respectively. The typical cubic cell shape of primary hepatocytes
often containing two nuclei could be seen in the iPSC-derived
hepatocyte-like cells (iCell®) and the co-culture systems
(HμREL™ and HepatoPac®). The HepG2 model was included
as a negative control as it has very limited metabolic activity, and
iPSC-derived hepatocyte-like cells (iCells®) were included due
to their future potential as an interesting tool lacking donor-to-
donor variability. To compare the in vitro models in terms of
metabolic activity, ametabolic activity index was calculated either
across the diverse set of phase I and phase II enzyme markers
(mean index shown as a line in Fig. 2) or across the ﬁve CYP
enzymes only (as given in Table II). Figure 2 and Table II show
that there is a similar average metabolic activity across all 11
enzymemarkers for HepaRG™ (at day 7), HμREL™ (at day 8),
and HepatoPac® (at day 8) as compared to the primary pooled
cryopreserved hepatocytes (at day 0) in suspension using
different lots. For iPSC-derived hepatocyte-like cells (iCell®,
at day 4) and HepG2 (at day 4), the metabolic activity was more
than tenfold lower on average. In terms of mean CYP activities,
the HepatoPac® and primary pooled cryopreserved hepatocytes
had a similar CYP index, showing that the studied CYP activities
in HepatoPac® at day 8 are equivalent to those of the primary
suspension cultures at day 0. HepaRG™ and HμREL™ had a
three to fourfold lower CYP activity index compared to
suspension cultures, which might be due to donor variability or
due to culture conditions. Comparing the single activities for the
different enzyme markers in HepaRG™, HμREL™, and
HepatoPac® versus primary pooled cryopreserved hepatocytes
in suspension, several differences were observed. Importantly,
the CYP2D6 activity differed between the three in vitro liver
models, e.g., 56-fold lower in HepaRG™, 14-fold lower in
HμREL™, and 2.5-fold lower in HepatoPac® as compared to
suspension cultures. Furthermore, theAOandFMOactivities for
HepaRG™, HμREL™, and HepatoPac® were reduced com-
pared to the suspension cultures. The AO activities of
HepaRG™ and HμREL™ were ﬁve to sixfold lower, whereas
the activity for HepatoPac® was threefold lower. For the FMO
activity, an eightfold lower activity was found in HμREL™ and a
539Metabolic Profiling of Long-Term Liver Models
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































threefold lower activity, on average, in HepaRG™ and
HepatoPac®. Furthermore, the AKR activity in HepaRG™
was increased (threefold) and similar in HμREL™ and
HepatoPac®. The UGT1A1 activity as determined by SN-38
glucuronide formation was two to threefold lower in HepaRG™,
HμREL™, and HepatoPac® as compared to the suspension
cultures. In HμREL™ and HepatoPac®, the NAT2 and UGT
activities were higher (two and threefold, respectively), whereas
in HepaRG™, the NAT2 activity was lower (twofold) and the
UGT activity was similar. For the SULT activity using 7-
hydroxycoumarin as the enzyme marker, an eightfold higher
formation of 7-hydroxycoumarin sulfate was observed in
HepatoPac® as compared to the suspension cultures, whereas
only a twofold increase or similar activity was seen in HμREL™
and HepaRG™, respectively. As HμREL™ and HepatoPac®
are co-culture models containing hepatocytes and non-
parenchymal cells, metabolite formation was also studied in
mouse embryonic 3T3 ﬁbroblasts, which are co-cultured in the
HepatoPac® system. As expected, no CYP-related metabolism
in the ﬁbroblast cultures was found, but signiﬁcant formations of
daunorubicinol (AKR enzyme marker, 50% of HepatoPac®), 7-
hydroxycoumarin glucuronide (UGT, 50% of HepatoPac®), and
SN38 glucuronide (UGT1A1, 20% of HepatoPac®) were
observed, which were subtracted from the metabolite formation
rates reported in Fig. 2 and Table I for the micropatterned
HepatoPac® system as the surface area occupied by ﬁbroblasts
and hepatocytes is speciﬁed (for details, see BMATERIALS
AND METHODS^). In summary, HepaRG™, HμREL™, and
HepatoPac® demonstrated metabolic activity similar to primary
suspension cultures and could qualify for use in intrinsic clearance
determinations of compounds.
In Vitro Clearance Assessment of Model Compounds:
Comparison between Long-Term In Vitro Liver Model and
Suspension Cultures from the Same Human Donor
After metabolic activity proﬁling of the different in vitro
long-term liver models, we further evaluated one representa-
tive, HepatoPac®, for in vitro clearance assessments using
reference compounds. For these reference compounds, mid-
azolam (CYP3A4), quinidine (CYP3A4), nifedipine
(CYP3A4), diclofenac (CYP2C9), warfarin (CYP2C9), tolbu-
tamide (CYP2C9), and dextromethorphan (CYP2D6), the
intrinsic clearances were determined in the HepatoPac®
system and compared to the suspension cultures from the
same donor (for details, see BMATERIALS AND
METHODS^, Eq. 1). In Fig. 3, the time–concentration
proﬁles for quinidine in the HepatoPac® system are exem-
pliﬁed. In HepatoPac®, quinidine concentrations decreased
to 5% after 4 days in comparison to 71% after 2 h in the
suspension cultures. The intrinsic clearance of quinidine in
HepatoPac® across six studies (different shipments, same
donor) was, on average, 12.4 μL min−1 mg−1 protein, with a
variability of 29%. This study-to-study variability of ∼30%
was deemed to be acceptable. The in vitro clearances were
then scaled by applying the well-stirred model using the
conventional approach as described in BMATERIALS AND
METHODS^ (Eqs. 8–12). Fraction unbound values in the
incubation media and human plasma were experimentally
determined and are listed in Table III together with the
blood-to-plasma ratios. The observed plasma clearances for
these model compounds were obtained from literature
sources and are listed in Supplemental 2 and 3. Figure 4
shows the comparison of the predicted scaled in vitro
unbound intrinsic clearance values of these model compounds
in HepatoPac® and in the suspension cultures from the same
human donor compared to the observed in vivo intrinsic
clearance values. Generally, the predictions for medium- to
high-clearance compounds, nifedipine (CYP3A4), midazolam
(CYP3A4), dextromethorphan (CYP2D6), and diclofenac
(CYP2C9), were similar in both in vitro systems, with a
tendency to higher predicted intrinsic clearance values of 1.8-
fold, on average, in the HepatoPac® incubations. For the
low-clearance compounds (quinidine (CYP3A4), warfarin,
and tolbutamide (CYP2C9)), hepatic clearances could be
predicted with conﬁdence from the HepatoPac®, whereas no
clearance values could be determined in the suspension
cultures for the very low-clearance compounds warfarin and
Fig. 1. Cell morphology of the different studied in vitro liver models.
a Human liver cancer cell line HepG2 (at day 4) with its epithelial-
like morphology containing one nucleus as compared to often two
nuclei of primary hepatocytes. b iPSC-derived hepatocyte-like cells
(iCell® at day 4). c Hepatic stem cell line HepaRG™ (at day 7) with
its typical irregular cell shape. dMicropatterned co-cultures of human
hepatocytes (unpooled) with mouse embryonic 3T3 ﬁbroblast cells
(HepatoPac®, at day 8). The micropatterned hepatocyte colony is
surrounded by ﬁbroblasts. e Co-cultures of pooled hepatocytes and
cells of a non-parenchymal, stromal type (HμREL™, at day 8)
showing primary hepatocytes with their typical cubic cell shape and
two nuclei. f Primary pooled cryopreserved hepatocytes in suspension
cultures (at day 0) showing the rounded cell morphology. Cells were
imaged with a ×10 magniﬁcation phase contrast by means of a Zeiss
Axio Vision SE64 Rel. 4.9.1 microscope (Carl Zeiss AG Corporate)
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tolbutamide. Supplemental 2 and 3 list the observed in vivo
(intrinsic) clearances and the predicted scaled in vitro intrinsic
clearance values for the HepatoPac® (underprediction aver-
age of 1.6) and primary pooled cryopreserved hepatocyte
suspension cultures (underprediction average of 2.9) from the
same human donor, respectively.
Nonlinear Mixed-Effects Approach to In Vitro Low Clearance
Assessments in Long-Term Liver Models
After the evaluation study with reference compounds,
we assessed the in vitro clearances for low turnover Roche
compounds in the long-term model. Figure 5 exempliﬁes the
observed concentration–time proﬁles for four of these
compounds (RO1, RO2, RO5, and RO8). For the determi-
nation of low in vitro intrinsic clearance values, a nonlinear
mixed-effects approach (Eqs. 2–7) instead of traditional
individual curve ﬁtting (Eq. 1) was applied to further boost
conﬁdence in the clearance assessment. For this approach, the
well of a 96-well plate was the statistical unit from which a
single concentration-time point was derived. To describe the
in vitro PK data, i.e., concentration–time proﬁles, a one-
compartment PK model was used with volume and either
linear (Eqs. 2 and 6) or nonlinear (Eqs. 3–5 and 7) clearance.
The lines in Fig. 5 represent the predictions for the observed
concentration–time proﬁles (symbols), which describe the
observed data well. Table IV summarizes the derived
elimination rates using the nonlinear mixed-effects approach
for three compounds with linear clearance. As shown in
Table IV, robust parameters could be derived for the
elimination rates in the co-cultures. Compound adsorption
phenomena and non-hepatic clearance by ﬁbroblasts in the
co-cultures were addressed by determining in addition the
elimination rates in ﬁbroblast cultures only (Table IV,
Fig. 2. Metabolic activities of in vitro liver models. The metabolite formation rates (black symbols) of 11 diverse phase I and phase II enzyme
markers were determined in 2D cultures of HepG2 (at day 4), iPSC-derived hepatocyte-like cells (iCell®, at day 4), HepaRG™ (at day 7),
HepatoPac® (at day 8), HμREL™ (at day 8), and primary pooled cryopreserved hepatocytes in suspension cultures (at day 0). The
metabolites were quantiﬁed by LC-MS/MS and the formation rates were derived for 1′-hydroxymidazolam (CYP3A4), dextrorphan
(CYP2D6), 4-hydroxydiclofenac (CYP2C9), hydroxybupropion (CYP2B6), hydroxytacrine (CYP1A2), benzydamine N-oxide (FMO),
daunorubicinol (AKR), 8-oxo-O6-benzylguanine (AO), N-acetyl-sulfamethazine (NAT2), SN-38 glucuronide (UGT1A1), 7-hydroxycoumarin
glucuronide (UGT), and sulfate (SULT). Gray symbols indicate the lower limit of quantiﬁcation for the studied metabolites (for details, see
Table I). The line represents the metabolic activity index calculated by averaging the determined metabolite formation rates of the 11 enzyme
markers (see Table II). For the HepatoPac® system, cryopreserved primary hepatocytes from a single donor were used (Lot 3121A,
BioreclamationIVT, Lot TLQ). Primary pooled cryopreserved hepatocytes were employed for the HμREL™ model (Lot HU1007,
BioreclamationIVT, Lot YMD (ﬁve donors)) and for the suspension culture studies (BioreclamationIVT, Lots ECO (ten donors), URK
(ﬁve donors), and JJR (ten donors)). The different lots of primary hepatocytes showed similar metabolic activities for the CYP and UGT/
SULT enzyme markers in the BioreclamationIVT lot characterization sheets (listed in Supplemental 6)
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controls). To derive the in vitro intrinsic clearance values in
hepatocytes, the elimination rates in the co-cultures were
corrected by the control rates and normalized by the protein
content, as described in BMATERIALS AND METHODS.^
For the fourth compound RO2, the clearance was nonlinear
and Km and Vm values of 2.19 μM (relative standard error
(rse) = 0.1%) and 19.6 pmol min−1 mg−1 protein (rse = 2%)
were estimated by applying a nonlinear PK model. Table V
summarizes the derived intrinsic clearance values for all the
compounds in the long-term cultures (Supplemental 4 and 5
list all the derived parameters in co-cultures and control
plates). For the clearance parameters, the variability for the
whole data set was, on average, 10%. This demonstrates a
signiﬁcant increase in conﬁdence for in vitro intrinsic
clearance determinations as compared to the suspension
cultures, where the clearance variability was, on average,
>80% for low-clearance compounds (Clint < 3 μL min
−1 mg−1
protein).
IVIVE of In Vitro Clearance Assessments
We then explored the in vitro to in vivo extrapolation
(IVIVE) for clearance by applying the well-stirred model
assessing different protein binding assumptions, e.g.,
conventional (20,21), direct (22,23), and the method
reported by Poulin et al. (24,25) (see Eqs. 8–16). For
that, the fractions unbound in the incubation media and
human plasma were experimentally determined and are
listed in Table III together with the blood-to-plasma
ratios. For the IVIVE of the Roche clinical drug
candidates tested in the HepatoPac® system, the direct
scaling approach gave rise to reasonable clearance predic-
tions in man with no under- or overprediction (average
fold error of 1.0) and a root mean square error (rmse) of
90. In comparison, the conventional scaling approach
showed a large underprediction of 6.4 (rmse = 52),
whereas the Poulin methodology reduced the under-
prediction to 1.6, on average, with a very low rmse of
15. The statistical parameters for the human hepatic
clearance predictions for the Roche compounds are listed
in Table V. Considering all of the statistical parameters,
the direct and the Poulin methods performed very
similarly, whereas the conventional scaling approach was
less favorable. For six out of eight compounds, the
predicted versus observed fold errors were, on average,
1.1 and 0.7 for the direct scaling (63% within twofold and
75% within threefold) and the Poulin methodologies (50%
within twofold and 75% within threefold), respectively.
For RO6 and RO7, a >6-fold underprediction or
Table II. Metabolic Activity Indices for HepG2 (at Day 4), iPSC-Derived Hepatocyte-Like Cells (iCell®, at Day 4), HepaRG™ (at Day 7),
HepatoPac® (at Day 8), HμREL™ (at Day 8), and Primary Pooled Cryopreserved Hepatocytes in Suspension Cultures (at Day 0 in Culture)
Metabolic activity indexa HepG2 iPSC-derived hepatocyte-like
cells (iCells®)
HepaRG™ HepatoPac® HμREL™ Suspension cultures
Enzyme markers all CYP all CYP all CYP (without 2D6) all CYP all CYP all CYP
Median 0.2 <0.1 0.1 0.1 2 2 (2) 4 3 2 1 3 3
Mean 0.6 <0.1 1.1 0.1 8 3 (4) 20 11 10 3 11 10
Geometric mean 0.3 <0.1 0.2 0.1 3 1 (2) 6 4 2 1 6 4
SEM 0.3 n.d. 0.6 0.1 4 2 (3) 10 8 6 2 4 6
Activities > LOQ 7 1 9 3 12 5 (4) 12 5 12 5 12 5
n.d. not deﬁned, LOQ limit of quantiﬁcation
aMetabolic activity index is the mean of the metabolite formation rates of either 11 diverse phase I and phase II enzyme markers (all) or of the
ﬁve CYP enzyme markers (CYP) or the four CYP enzyme markers without CYP2D6. For the HepatoPac® system, cryopreserved primary
hepatocytes from a single donor were used (Lot 3121A, BioreclamationIVT, Lot TLQ). Primary pooled cryopreserved hepatocytes were
employed for the HμREL™ model (Lot HU1007, BioreclamationIVT, Lot YMD (ﬁve donors)) and for the suspension culture studies
(BioreclamationIVT, Lots ECO (ten donors), URK (ﬁve donors), and JJR (ten donors)). The different lots of primary hepatocytes showed
similar metabolic activities for the CYP and UGT/SULT enzyme markers in the BioreclamationIVT lot characterization sheets (listed in
Supplemental 6)
Fig. 3. Quinidine concentrations as a function of time in the cell
medium of long-term human hepatocyte co-cultures (HepatoPac®)
from six independent studies. The line represents the prediction
based on nonlinear mixed-effects modeling. The intrinsic clearance of
quinidine was, on average, 12.4 μL min−1 mg−1 protein with a study-
to-study variability of 30%. For comparison using individual curve
ﬁt t ing (two-stage approach), an intrinsic clearance of
11.6 μL min−1 mg−1 protein was determined with a study-to-study
variability of 36%. Thus, the nonlinear mixed-effects and two-stage
approaches give rise to similar results for compounds with linear
clearance and decent turnover (in general, intrinsic clearance values
>3 μL min−1 mg−1 protein)
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overprediction was found for all protein binding assump-
tions, respectively. As the Poulin methodology is reported
to perform best for compounds with high binding to plasma
proteins, the IVIVE of a subset with fu < 0.15 was explored. For
this small data set, however, no further gain in performance
could be observed using this scaling approach. Figure 6
exempliﬁes for the direct scaling approach the correlation
between the predicted scaled in vitro and observed in vivo
intrinsic clearances of the Roche compounds. In addition,
Table VI summarizes the in vitro intrinsic clearance values and
the scaled predicted and observed clearances.
DISCUSSION
In drug discovery programs, the determination of in vitro
intrinsic clearances is routinely conducted using microsomes or
hepatocytes,which are still the industry standard in vitro livermodels.






















Midazolam Neutral 325.8 3 5.8 CYP3A4 0.02 Albumin 0.96/0.19 0.67 Medium
Quinidine Base 324.4 2.0 8.7,
4.4
CYP3A4 0.18 AAGP 1.0/1.0 0.90 Low
Nifedipine Neutral 346.3 2.0 – CYP3A4 0.04 Albumin 1.0/0.50 0.65 Medium
Diclofenac Acid 296.1 1.0 3.9 CYP2C9 0.009 Albumin 0.86/0.02 0.55 Medium
Warfarin Neutral 308.3 n.d. 4.8 CYPs 2C9, 3A4 0.015 Albumin 0.82/0.18 0.55 Low
Tolbutamide Acid 270.3 0.5 5.1 CYP2C9, UGTs 0.05 Albumin 1.0/0.35 0.75 Low
Dextromethorphan Base 271.4 1.5 9.8 CYPs 2D6, 3A4 0.4 Albumin 1.0/1.0 1.0 Low–high
RO1 Base 351.3 0.9 8.1 CYP3A4 0.45 Albumin:
0.41, 1.0
0.91/– 1.50 Low

































RO6 Base 416.5 2.2 3.1,
10.9
CYP3A, FMO 0.13 Albumin:
0.28, 0.48
0.89/– 1.48 Low
RO7 Neutral 328.4 3.8 – CYPs 3A, 2C19 0.02 Albumin:
0.03, 0.86
0.93/– 0.62 Low














MW molecular weight, pKa acid dissociation constant, HSA human serum albumin, BPP blood plasma partitioning
aLogD 7.4 is the octanol–water partitioning
b fu is the fraction unbound in human plasma
c fuHSA: fraction unbound in 45 g/L HSA buffer solution. fuAAGP: fraction unbound in 0.7 g/L α1 acid glycoprotein buffer solution (AAGP)
d fuinc: fraction unbound in incubation medium
eCompounds with in vivo plasma clearance to liver blood ﬂow ratios <0.3 are labeled as low and ratios >0.7 are labeled as high-clearance
compounds. Compounds with ratios between these limits are categorized as medium clearance
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Sensitive Range for In Vitro Clearance Assessments and
In Vivo Relevance
For intrinsic clearance determinations in microsomes, the
sensitive range is generally deﬁned across the pharmaceutical
industry as between 10 and 1000 μL min−1 mg−1 protein (27).
In this range, the clearance values can be determined with
conﬁdence, e.g., with a coefﬁcient of variation (CV) of ≤30%
for multiple determinations. As the maximal incubation time
of the hepatocyte suspension cultures is 2–4 h as compared to
microsomes (0.5–1 h), the sensitive range for in vitro clear-
ance determination in hepatocyte suspension cultures is
lower, e.g., between 3 and 200 μL min−1 mg−1 protein
(CV≤ 30%) (4). For the majority of drugs, the volume of
distribution is between the blood volume of 0.1 and 10 L/kg
(28). Clearance values are between 0.2 and 60 L/h to enable
potential twice- or once-daily drug dosing regimens. Thus,
in vitro clearance values could be well below 1 μL min−1 mg−1
protein depending on the physicochemical properties of the
compounds (BPP and fu values) (4,29). With the current
development of engineered in vitro liver models offering
increased hepatocyte life span, one can now extend the
conﬁdence in clearance predictions towards the low range,
which is important for once-daily dosing regimens.
As a prerequisite for clearance prediction in man, the
enzyme activities need to be conserved during in vitro long-
term culturing of the hepatocytes. We therefore studied the
metabolic activities with a diverse set of phase I and phase II
enzyme markers across different models.
Metabolic Activity Assessment of In Vitro Liver Models and
Comparison
The metabolic proﬁling study showed similar metabolic
activities, on average, for HepaRG™ (at day 7), HμREL™
(at day 8), and HepatoPac® (at day 8) as compared to
primary pooled cryopreserved hepatocytes in suspension (at
day 0). However, pronounced differences in metabolic
activities were observed for CYP2D6. The underprediction
for CYP2D6 metabolized compounds in HepaRG™ has
already been reported due to a CYP2D6-deﬁcient donor
(11,30,31). However, the fold of underprediction seems to
vary between the applied enzyme markers due to potential
metabolism by multiple CYP enzymes (11,30–32). For
example, the intrinsic clearances in HepaRG™ as compared
to suspension cultures were decreased more for dextrome-
thorphan and metoprolol than for propranolol (11,30).
Several factors, such as differences in the metabolism of
enzyme markers, study design, and donor-to-donor variabil-
ity, complicate a meta-analysis comparing the metabolic
activities of new in vitro liver models to those of primary
hepatocytes in suspension cultures. Furthermore, reduced
activities of FMO and AO were found in all long-term in vitro
liver models as compared to suspension cultures in our
metabolic proﬁling study. Interestingly, both enzymes are
using ﬂavin adenine dinucleotide as prosthetic group. The
effect of time on AO activity, i.e., substantial loss of activity
within 24 h after isolation of hepatocytes from human liver
tissue, was recently reported by Hutzler et al. (33). Further-
more, substantial donor variability of the AO activity was
observed by these authors (33) in primary hepatocyte
suspension cultures. For FMO, loss of enzyme function due
to either liver tissue preparation (34,35) or with time in plated
human primary hepatocytes was found previously (36). Thus,
either biological variability or in vitro conditions could
explain the reduced AO and FMO activities in the long-
Fig. 4. Comparison of in vitro intrinsic unbound clearances derived
from long-term human hepatocyte co-cultures (HepatoPac®, white
bars) and cryopreserved primary human hepatocyte suspension
cultures (black bars, same human donor) to the observed in vivo
intrinsic clearance range (lines) for seven reference compounds in
man. na not applicable. Conventional scaling for the clearances was
applied as described in BMATERIALS AND METHODS.^ The
applied fraction unbound in cell medium and human plasma and the
blood plasma partitioning values of the model compounds, which
were used for the conventional scaling approach, are listed in
Table III. The shown in vitro and observed in vivo intrinsic clearance
values with their predicted versus observed fold errors for the
reference compounds are given in Supplemental 2 and 3
Fig. 5. Time–concentration proﬁles of Roche clinical drug candidates
in the long-term in vitro human liver model, HepatoPac®. a RO1 at
concentrations of 1 and 3 μM. b RO8 at concentrations of 0.3 and
1 μM. c, d RO5 (c) and RO2 (d) at concentrations of 0.3, 1, 3, and
10 μM. Lines represent the predictions based on pharmacokinetic
modeling using a nonlinear mixed-effects approach
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term in vitro systems after 7–8 days in culture. It will need
further studies to understand whether loss of enzyme function
occurs, especially during the long-term culture of 8–15 days,
and to which extent it affects the IVIVE of compounds
metabolized by these enzymes. In addition, the ﬁndings of
signiﬁcant AKR and UGT metabolism in the ﬁbroblasts of
the co-culture models, such as HepatoPac® and HμREL™,
need to be addressed as they complicate metabolite identiﬁ-
cation and clearance prediction for compounds with low or
non-CYP-related metabolism.
IVIVE of In Vitro Clearance Assessments
To explore the IVIVE for mainly CYP-metabolized model
compounds, the intrinsic clearances were determined in one
in vitro model, HepatoPac®. The derived intrinsic clearance
values were then compared to those in suspension cultures from
the same donor after applying the well-stirred model using the
conventional scaling approach. The seven model compounds
were midazolam (CYP3A4), quinidine (CYP3A4), nifedipine
(CYP3A4), diclofenac (CYP2C9), warfarin (CYP2C9), tolbuta-
mide (CYP2C9), and dextromethorphan (CYP2D6). The
prediction of hepatic clearances derived from HepatoPac®
showed an underprediction of 1.6, on average, compared to
those of the suspension cultures with an underprediction of 2.9.
The twofold lower underprediction average for predicted
clearances in HepatoPac® was in line with the twofold higher
metabolic activity in HepatoPac® as compared to the suspen-
sion cultures from the same donor. Our results agree well with
the ﬁnding of Chan et al. (10), who also reported a twofold
higher metabolic capacity in HepatoPac® compared to
suspended hepatocytes from a different donor and using
different model compounds. For low-clearance compounds,
warfarin and tolbutamide, the long-term system was clearly
superior for the prediction of hepatic clearances as no clearance
values could be determined in the suspension cultures. The
better performance of HepatoPac® for low-clearance com-
pounds was also shown by Chan et al. (10), who reported the
Table IV. In Vitro Elimination Rates (ke) for Three Roche Clinical Drug Candidates in Long-Term Hepatocyte Co-cultures from Human
(HepatoPac®) and in Control Plates of Mouse Embryonic 3T3 Fibroblasts








(μL min−1 mg−1 protein)
RO1 5.53e−005 (6) 0.0978 (10) 8.89e−006 (29) 0.070 (10) 0.97
RO5 2.22e−004 (5) 0.159 (14) 1.01e−005 (25) 0.162 (10) 4.3
RO8 2.94e−005 (11) 0.0892 (10) 8.3e−006 (23) 0.0513 (10) 0.46
The elimination rates and residual variabilities with their relative standard errors (rse, %) were derived by pharmacokinetic modeling using a
nonlinear mixed-effects approach. The control plates were used to account for non-hepatic in vitro clearance, such as compound adsorption or
clearance by ﬁbroblasts in the co-culture system. To derive the in vitro intrinsic clearance values, the elimination rates of the co-culture were
corrected by subtracting the control rates multiplied by 0.75 and normalized by the protein content, as described in BMATERIALS AND
METHODS^
Table V. Statistics for Hepatic Clearance Predictions from In Vitro Data for Roche Clinical Drug Candidates in Man Using the Well-Stirred
Model
Statistics Protein binding assumptions
Conventional (20,21): alla/subsetb Direct (22,23): alla/subsetb Poulin (24,25)c: alla/subsetb
afed 6.4/8.2 1.0/0.7 1.6/1.4
aafee 6.4/8.2 3.1/2.4 2.6/2.1
rmsef 52/66 90/114 15/18
CCCg 0.1/0.1 0.3/0.2 0.3/0.3
Maximal fold errorh 75/75 22/22 12/12
Within twofoldi (%) 0/0 63/37.5 50/25
Within threefoldi (%) 25/12.5 75/37.5 75/37.5
Within ﬁvefoldi (%) 50/25 75/37.5 75/37.5
Number of compounds 8/5 8/5 8/5
aThe data set contains eight compounds, RO1–RO9. RO2 human data not yet available
bThe subset contains RO4–RO7 and RO9, which have fraction unbound values <0.15
c For the Poulin protein assumption approach, a plasma-to-liver concentration ratio of 12.5 was used as albumin is the major binding protein for
the compounds RO1–RO9. pH gradient effects were taken into account, as outlined in Poulin et al. (24,25)
dAverage fold error (see Eq. 14)
eAbsolute average fold error (see Eq. 15)
fRoot mean squared error (see Eq. 16)
gConcordance correlation coefﬁcient global (26)
hMaximal predicted versus observed fold error (see Eq. 13)
i Percentage of compounds which had predicted versus observed fold errors within two, three, or ﬁvefold
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prediction of low-clearance reference compounds within two-
fold for six out of ten in HepatoPac® cultures. Recently, Bonn
et al. (11) exploredHepaRG™, plated primary hepatocytes, and
HμREL™ for low clearance determination. The authors
concluded that plated primary hepatocytes and HμREL™
delivered similar intrinsic clearance values and could predict
the in vivo clearance within threefold for 70% of the reference
compoundswith an average fold error of 2, with slightly superior
performance of the HμREL™ system. In their hands,
HepaRG™ data were less predictive, giving rise to a prediction
within threefold for only 50%of compounds (average fold error,
2.9). The inclusion of CYP2D6 metabolized compounds in their
evaluation of HepaRG™ and the selection of different incuba-
tion times, 24 h for HepaRG™, 12 h for plated hepatocytes, and
72 h for HμREL™, could, however, have inﬂuenced the overall
system performance, as Zanelli et al. (32) reported earlier that
in vivo clearances of 26 different reference compounds could be
predicted within twofold when applying the HepaRG™ system.
To evaluate the performance of HepatoPac® for clear-
ance prediction of compounds occupying a different chemical
space compared with mainly CYP-metabolized reference
compounds, we assessed the intrinsic clearances and the
IVIVE for nine Roche compounds. For the determination of
the intrinsic clearances in the long-term model, we employed
pharmacokinetic modeling using a nonlinear mixed-effects
approach instead of the traditional individual curve ﬁtting.
With this approach, signiﬁcant improvement in precision for
low clearance estimations could be gained, giving rise to a
variability of ∼10%, on average, for the intrinsic clearance
parameter compared to >80% in the suspension cultures. In
addition, the nonlinear mixed-effects approach gave informa-
tion on the validity of the chosen pharmacokinetic model as
well as the residual variability in contrast to the traditional
curve ﬁtting (two-stage approach). Tsamandouras et al. (37)
just recently studied inter-individual variability in drug
metabolism in vitro using a 3D liver system and nonlinear
mixed-effects modeling. These authors characterized six
different donors in their 3D liver system and determined
donor variability for the in vitro clearances of reference
compounds. This work of Tsamandouras et al. (37)
highlighted the inﬂuence of donor variability and the need
for the development of multiple donor pools to minimize the
risk of prediction bias due to donor selection, especially for
drugs which are metabolized by non-CYP enzymes. It is
therefore an important development that long-term multiple
donors systems are now becoming available.
For the IVIVE of clearance, we applied the well-stirred
model exploring different protein binding assumptions, i.e.,
conventional (20,21), direct (22,23), and the method reported
Fig. 6. Comparison of the in vitro and in vivo intrinsic unbound
clearances for Roche clinical drug candidates in man. The in vitro
intrinsic clearance values were determined in long-term hepatocyte
co-cultures from human (HepatoPac®). The well-stirred model and
direct scaling were used as described in BMATERIALS AND
METHODS.^ The applied fraction unbound in human plasma and
the blood plasma partitioning values are listed in Table III. In
addition, the line of unity and the twofold (dashed) and fourfold
(dotted) error margins are given. Most of the studied compounds are
within a twofold error margin
Table VI. In Vitro and Observed In Vivo Clearances and Intrinsic Unbound Clearances with their Predicted Versus Observed Fold Errors for
Roche Clinical Drug Candidates in Man




















RO1 0.97 5.7 2.4 3–6 7–16 0.4–0.8
RO2 1.6–7.9 91.8–453.4 3.1–7.5 n.d. n.d. n.d.
RO3 0.44 3.0 1.1 1.3 4 0.9
RO4 1.1 18.9 2.6 1.7 12 1.6
RO5 4.3 169 6.7 3–8 55–235 0.7–3.1
RO6 0.26 5.4 0.7 4–8 35–81 0.1–0.2
RO7 1.5 240 3.0 0.17 11 22
RO8 0.46 2.9 1.2 3.6 9.6 0.3
RO9 0.89 21 2.2 1.4 14 1.6
The in vitro intrinsic clearance values were determined in long-term human hepatocyte co-cultures (HepatoPac®). The well-stirred model with
direct scaling was used as described in BMATERIALS AND METHODS.^ The applied fraction unbound in human plasma and the blood
plasma partitioning values, which were used for the scaling approach, are listed in Table III
n.d. not deﬁned
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by Poulin et al. (24,25), where protein-facilitated uptake is
taken into account by replacing the fraction unbound in
plasma by the fraction unbound in liver (38–41). The
conventional approach showed a large underprediction of
6.4 for the Roche compounds, whereas the direct and Poulin
scaling approaches gave rise to reasonable clearance predic-
tions in man with average fold errors of 1.0 and 1.6,
respectively. For six out of eight Roche compounds, the
predicted versus observed fold errors were, on average, 1.1
and 0.7 for the direct scaling (63% within twofold and 75%
within threefold) and the Poulin methodology (50% within
twofold and 75% within threefold), respectively. For RO6
and RO7, however, a >6-fold underprediction or overpredic-
tion, respectively, was found for all protein binding assump-
tions. The underprediction for RO6 could be due to reduced
FMO metabolism and similar clearance rates in co-cultures
and control ﬁbroblasts giving rise to large uncertainty in the
human clearance prediction. For RO7, the overprediction
from in vitro in man is currently not yet understood.
Interestingly, the conventional scaling showed better perfor-
mance for the mainly CYP-metabolized reference compounds
in the long-term co-culture system HepatoPac as compared to
the direct scaling approach. The better performance of direct
scaling for the in vivo clearance prediction of Roche com-
pounds might be due to the involvement of non-CYP enzymes
and transporters, which gives rise to larger underprediction
compared to CYP-metabolized reference compounds (42,43).
These results demonstrated that the performance of the scaling
approach was dependent on the applied in vitro liver model,
the chemical space of the selected compound set, i.e., their
physicochemical properties, such as plasma protein binding,
and the involved clearance routes. This dependency of the
scaling approaches and their performance are widely discussed
(27,44–46). Recently, Lin et al. (47) reported that HepatoPac®
showed a better overall performance in predicting 73% of the
drug clearances within twofold when applying conventional
scaling for low- to very low-clearance compounds
(≤1 mL min−1 kg−1) and direct scaling for medium- to high-
clearance compounds (>1 mL min−1 kg−1). For drugs highly
bound in plasma and drugs bound to albumin, Poulin et al. (38)
could demonstrate that their scaling approach performed
better in terms of human clearance predictions from suspen-
sion cultures, giving rise to an average fold error (afe) of 1.1,
followed by the regression method, direct scaling, and conven-
tional approach with afe values of 1.3, 2.2, and 0.52,
respectively, for a data set of 38 reference compounds. The
hypothesis of protein-facilitated uptake is further supported by
the fact that the presence of serum in the in vitro model
inﬂuences the performance of the scaling approach. Blanchard
et al. (48) showed very early on that prediction of human
clearance was improved in the presence of serum. This was
conﬁrmed by Parrott et al. (49), who reported human clearance
prediction within twofold from intrinsic clearance values in
suspension cultures containing 10% serum and physiologically
based pharmacokinetic (PBPK) modeling. Furthermore, Chao
et al. (50) showed better performance of plated hepatocytes in
respect to clearance prediction in the presence of 4% albumin,
which is equivalent to the albumin concentration in the human
plasma. Thus, the addition of plasma proteins may also beneﬁt
clearance prediction from long-term in vitro liver models, as
demonstrated for suspension and plated hepatocyte cultures.
Finally, new static and dynamic IVIVE methods are
explored, such as the integration of non-hepatic clearance
routes (51,52), the extended clearance concept (53), and
mechanistic PBPK modeling (54,55), to address the
underprediction of clearance for some compound classes.
For example, the extended clearance concept takes into
account metabolic and transporter clearance for compounds,
which are actively taken up into the tissue. For these
mechanistic approaches, key input parameters, such as
metabolic and transporter clearance, need to be determined
from in vitro models with conﬁdence. For low-clearance
compounds, which are actively taken up by the liver, the
determination of the metabolic intrinsic clearance is however
a challenge. On the one hand, as discussed, its determination
is beyond the sensitive range of the short-term in vitro liver
models, i.e., microsomes or suspension cultures. On the other
hand, using long-term in vitro liver models gives rise to
apparent intrinsic clearance values as these models show
active uptake and biliary efﬂux of compounds under steady-
state conditions. Additional work and detailed characteriza-
tion of the expression and functional activity for phase II
enzymes and transporters are required in order to understand
whether these systems can be used to determine the rates of
the key clearance processes. Furthermore, research is needed
to see whether the derived in vitro rates reﬂect the in vivo
situation and can be applied in mechanistic modeling efforts
to further improve clearance predictions in man.
CONCLUSION
In essence, the human liver cancer cell line HepG2, induced
pluripotent stem cell-derived hepatocyte-like cells (iCell®), the
hepatic stem cell line HepaRG™, and hepatocyte co-cultures
(HμREL™ and HepatoPac®) were compared to primary
hepatocyte suspension cultures with respect to their key meta-
bolic activities. The long-term in vitro liver models, HepaRG™,
HμREL™, and HepatoPac®, showed similar mean metabolic
activities across 11 metabolic enzyme markers as compared to
primary hepatocyte suspension cultures using different hepato-
cyte donors and qualify for use in intrinsic clearance determina-
tions of compounds. For iCell® and HepG2, the metabolic
activity was more than tenfold lower. As one representative
model, the micropatterned HepatoPac® system was further
assessed in terms of clearance predictions. The HepatoPac®
system performed similarly for medium- to high-clearance drugs
(CYP-mediated) as compared to the suspension cultures. For the
majority of high metabolically stable compounds, however, it was
superior, giving rise to clearance prediction in man within a
twofold error using the evaluated donor lot. Thus, clearance
predictions for low-clearance clinical drug candidates, which
differ in their physicochemical properties and clearance routes
from literature compounds, could be reliably improved by
applying in vitro long-term models in combination with pharma-
cokinetic modeling using a nonlinear mixed-effects approach.
The increased cost for such models is balanced by the beneﬁts of
improved clearance predictions for low-clearance compounds
and the enabling of sophisticated in vitro disposition studies under
steady-state conditions. Further research is needed to understand
whether transporter activity and drug metabolism by non-CYP
enzymes, such as UGTs, SULTs, AO, and FMO, are comparable
to the in vivo situation in these long-term culture models.
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